Stock INAB IN8BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. IN8bio, Inc.

Equities

INAB

US45674E1091

Delayed Nasdaq
Other stock markets
 09:31:40 07/05/2024 pm IST 		5-day change 1st Jan Change
1.018 USD +1.99% Intraday chart for IN8bio, Inc. -0.20% -26.23%
30/04 In8bio, Inc. Doses First Patient in Phase 2 Clinical Trial of Inb-400 in Newly Diagnosed Glioblastoma CI
10/04 Top Premarket Gainers MT

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Laidlaw Initiates Coverage on IN8bio With Buy Rating, $7.50 Price Target
MT
JonesTrading Starts IN8bio With Buy Rating, $5 Price Target
MT
EF Hutton Initiates IN8bio at Buy With $8 Price Target
MT
B. Riley Downgrades IN8bio to Neutral From Buy, Notes Limited Catalysts, Cash; Lowers Price Target to $3 From $9
MT
HC Wainwright Starts IN8bio at Buy with $14 Price Target
MT
B. Riley Lowers IN8bio's Price Target to $9 from $19 After Revising Cost Capital Assumptions, Keeps Buy Rating
MT
IN8BIO : Mizuho Securities Starts IN8bio at Buy With $12 Price Target
MT
IN8BIO : B. Riley Starts IN8bio at Buy with $19 PT, Ascribes Value to Glioblastoma Multiforme Program
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. INAB Stock
  4. News IN8bio, Inc.
  5. Analyst Reco.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW